Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katrina S Pedersen

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2019
Small Bowel Adenocarcinoma: Etiology, Presentation, and Molecular AlterationsKatrina S Pedersen, Kanwal Raghav, Michael J Overman
Hematology/Oncology Clinics of North America|May 16, 2022
Immunotherapy for Colorectal CancerReetu Mukherji, Benjamin A Weinberg, Katrina S Pedersen
Advances in Radiation Oncology|February 4, 2022
Oncology Trainee Perceptions of the Prior Authorization Process: A National SurveyHyun Kim, Amar Srivastava, Prashant Gabani, et al.
Targeted Oncology|December 10, 2025
Translational Relevance of the Genomic Landscape of KRAS<sup>G12D</sup>-Mutant Colorectal and Pancreatic CancersKhalid Jazieh, Jill Tsai, Sheila Solomon, et al.
Investigational New Drugs|May 9, 2015
Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium studyKatrina S Pedersen, George P Kim, Nathan R Foster, et al.
European Journal of Human Genetics : EJHG|December 15, 2010
Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counselingRobert R McWilliams, Eric D Wieben, Kari G Rabe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2025
Identification of Candidate Alterations Mediating KRASG12C Inhibitor Resistance in Advanced Colorectal and Pancreatic CancersKhalid Jazieh, Jill Tsai, Sheila Solomon, et al.
Plos One|April 2, 2011
Leukocyte DNA methylation signature differentiates pancreatic cancer patients from healthy controlsKatrina S Pedersen, William R Bamlet, Ann L Oberg, et al.
Hepatology Communications|October 12, 2022
Risk of nonalcoholic fatty liver disease and associations with gastrointestinal cancersScott McHenry, Xiaoyu Zong, Mengyao Shi, et al.
Investigational New Drugs|March 19, 2021
Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I studyKatrina S Pedersen, Patrick M Grierson, Joel Picus, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2019
Small Bowel Adenocarcinoma: Etiology, Presentation, and Molecular AlterationsKatrina S Pedersen, Kanwal Raghav, Michael J Overman
Hematology/Oncology Clinics of North America|May 16, 2022
Immunotherapy for Colorectal CancerReetu Mukherji, Benjamin A Weinberg, Katrina S Pedersen
Advances in Radiation Oncology|February 4, 2022
Oncology Trainee Perceptions of the Prior Authorization Process: A National SurveyHyun Kim, Amar Srivastava, Prashant Gabani, et al.
Targeted Oncology|December 10, 2025
Translational Relevance of the Genomic Landscape of KRAS<sup>G12D</sup>-Mutant Colorectal and Pancreatic CancersKhalid Jazieh, Jill Tsai, Sheila Solomon, et al.
Investigational New Drugs|May 9, 2015
Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium studyKatrina S Pedersen, George P Kim, Nathan R Foster, et al.
European Journal of Human Genetics : EJHG|December 15, 2010
Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counselingRobert R McWilliams, Eric D Wieben, Kari G Rabe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2025
Identification of Candidate Alterations Mediating KRASG12C Inhibitor Resistance in Advanced Colorectal and Pancreatic CancersKhalid Jazieh, Jill Tsai, Sheila Solomon, et al.
Plos One|April 2, 2011
Leukocyte DNA methylation signature differentiates pancreatic cancer patients from healthy controlsKatrina S Pedersen, William R Bamlet, Ann L Oberg, et al.
Hepatology Communications|October 12, 2022
Risk of nonalcoholic fatty liver disease and associations with gastrointestinal cancersScott McHenry, Xiaoyu Zong, Mengyao Shi, et al.
Investigational New Drugs|March 19, 2021
Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I studyKatrina S Pedersen, Patrick M Grierson, Joel Picus, et al.
Pageof 3